Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Hodgkin's lymphoma Stories

2013-06-27 16:25:11

WHITE PLAINS, N.Y., June 27, 2013 /PRNewswire/ -- Gilles B. Legault, Senior Counsel, Global Legal Affairs at Canadian National Railway Company (CN), has been elected to the National Board of Directors of The Leukemia & Lymphoma Society (LLS), effective July 1, 2013. His term will run through June 30, 2016. (Photo: http://photos.prnewswire.com/prnh/20130627/NY39897) Legault has been with CN in Montreal since August 2000. He also serves as Chairman of the Board of Directors of...

2013-06-25 12:30:44

A Lake Success, NYBoard Certified physician specializing in Hematology/Oncology, Dr. Jonathan E. Kolitz, is a Castle Connolly Top Doctor for 2013. LAKE SUCCESS, N.Y., June 25, 2013 /PRNewswire-USNewswire/ -- Castle Connolly Medical Ltd., America's trusted source for identifying Top Doctors, has selected Lake Success's Hematology/Oncology specialist Dr. Jonathan E. Kolitz for inclusion in its highly selective list of Regional Top Doctors this year. (Photo:...

2013-06-20 23:34:37

Latest results of Phase 2 study confirm high rate of response, remission In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in...

2013-06-20 23:30:02

Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with mantle cell lymphoma (MCL). Both studies, co-led by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC —...

2013-06-20 16:27:14

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor in patients with Waldenstrom's Macroglobulinemia (WM). Pharmacyclics is jointly developing ibrutinib with Janssen Research & Development, LLC. The data were presented today at the International Conference on Malignant Lymphoma (ICML), taking place in Lugano,...

2013-06-20 00:21:44

SUNNYVALE, Calif., June 19, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that The New England Journal of Medicine (NEJM) published results of a Phase 2 study evaluating the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in patients with relapsed/refractory mantle cell lymphoma (MCL) online. These data suggested ibrutinib may be effective and generally well-tolerated in patients with relapsed/refractory MCL. Results of a...

2013-06-19 16:26:56

A second study in relapsed/refractory chronic lymphocytic leukemia (CLL) also published in the online edition RARITAN, N.J., June 19, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced that a study published online in The New England Journal of Medicine (NEJM) demonstrates treatment with ibrutinib, an investigational oral Bruton's tyrosine kinase (BTK) inhibitor, resulted in an overall response rate of 68%, with 47% of patients achieving a partial...

2013-06-19 08:29:06

-TNT Fuels 300 New Research Programs to Discover Breakthrough Treatments& Cures- WHITE PLAINS, N.Y., June 19, 2013 /PRNewswire/ -- This year alone, The Leukemia & Lymphoma Society (LLS) is supporting more than 300 research projects with one goal in mind: Discovering lifesaving therapies for blood cancer patients. And in 2013, "Team In Training" (TNT), a flagship LLS fundraising campaign and the world's first and largest endurance sports training program, is marking its...

2013-06-17 08:29:05

Analysis Evaluates Response Rates in Patients with 17p Deletion, Fludarabine-Refractory CLL NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients...

2013-06-17 00:21:17

- Results Presented at 18th Congress of the European Hematology Association - SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from sub-set analyses of data from the Phase 3 EXTEND, or PIX301, clinical trial of PIXUVRI(®) (pixantrone). The analyses evaluated the efficacy of PIXUVRI in the subset of patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), as confirmed by central...